Wikipedia
Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.
The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.
advertisement
“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Generate Biomedicines machine learning biotech raises $273M
Next article： Medicare details structure of new drug price negotiation program
Next article： Medicare details structure of new drug price negotiation program
